Literature DB >> 29274372

Single grading vs double grading with adjudication in the telemedicine approaches to evaluating acute-phase retinopathy of prematurity (e-ROP) study.

Ebenezer Daniel1, Wei Pan2, Graham E Quinn3, Eli Smith2, Agnieshka Baumritter4, Gui-Shuang Ying2.   

Abstract

PURPOSE: To evaluate the sensitivity and specificity of single, independent, nonphysician trained reader (TR) gradings in the Telemedicine Approaches to Evaluating Acute-phase Retinopathy of Prematurity (e-ROP) study.
METHODS: Secondary analyses of image grading results from 1,235 infants of birth weights <1251 g. Two of three TRs independently graded image sets; discrepancies were adjudicated by the reading center director (an ophthalmologist) to reach final grading. Sensitivity and specificity of each TR grading and final grading was calculated by comparing gradings to clinical examination results.
RESULTS: Of 7,808 double graded image sets, TR1 graded 5,165; TR2, 3,787; and TR3, 6,664. Compared to final grading for referral warranted retinopathy of prematurity (RW-ROP), two TRs had relatively lower sensitivity (TR1, 75% vs 79% [P = 0.03]; TR2, 73% vs 77% [P = 0.02]) and specificity (TR1, 80% vs 83% [P < 0.001]; TR2, 82% vs 83% [P = 0.09]). TR3 had similar sensitivity (83% vs 83% [P = 0.78]) and specificity (83% vs 84% [P = 0.02]). Compared to final grading, TR1 had lower sensitivity for zone I ROP (47% vs 56% [P = 0.04]) and stage ≥3 ROP (71% vs 77% [P = 0.002]); TR2 had lower sensitivity for stage ≥3 ROP (69% vs 77% [P < 0.001]) and lower specificity for all three components (P < 0.001); TR3 had lower sensitivity for detecting plus disease (23% vs 35% [P < 0.001]) and similar sensitivity for zone I ROP and stage ≥3 ROP.
CONCLUSIONS: There is a small but significant decrease in the sensitivity and specificity for RW-ROP when single-reader grading is compared to double adjudicated grading.
Copyright © 2017 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29274372      PMCID: PMC5826856          DOI: 10.1016/j.jaapos.2017.09.005

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  20 in total

1.  Accuracy and reliability of remote retinopathy of prematurity diagnosis.

Authors:  Michael F Chiang; Jeremy D Keenan; Justin Starren; Yunling E Du; William M Schiff; Gaetano R Barile; Joan Li; Rose Anne Johnson; Ditte J Hess; John T Flynn
Journal:  Arch Ophthalmol       Date:  2006-03

2.  Inter-expert and intra-expert agreement on the diagnosis and treatment of retinopathy of prematurity.

Authors:  Andreas Gschließer; Eva Stifter; Thomas Neumayer; Elisabeth Moser; Andrea Papp; Niklas Pircher; Guido Dorner; Stefan Egger; Nenad Vukojevic; Isabel Oberacher-Velten; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2015-05-21       Impact factor: 5.258

3.  Color fundus photography versus fluorescein angiography in identification of the macular center and zone in retinopathy of prematurity.

Authors:  Samir N Patel; Michael A Klufas; Michael C Ryan; Karyn E Jonas; Susan Ostmo; Maria Ana Martinez-Castellanos; Audina M Berrocal; Michael F Chiang; R V Paul Chan
Journal:  Am J Ophthalmol       Date:  2015-01-28       Impact factor: 5.258

4.  Comparison of profile of retinopathy of prematurity in semiurban/rural and urban NICUs in Karnataka, India.

Authors:  Krishna R Murthy; Praveen R Murthy; Dhwani A Shah; Madhav R Nandan; Niranjan H S; Naveen Benakappa
Journal:  Br J Ophthalmol       Date:  2013-04-19       Impact factor: 4.638

5.  Trends in the Screening and Treatment of Retinopathy of Prematurity.

Authors:  Rebecca J Vartanian; Cagri G Besirli; John D Barks; Chris A Andrews; David C Musch
Journal:  Pediatrics       Date:  2016-12-14       Impact factor: 7.124

6.  Impact of number and quality of retinal images in a telemedicine screening program for ROP: results from the e-ROP study.

Authors:  David Morrison; Erick D Bothun; Gui-Shuang Ying; Ebenezer Daniel; Agnieshka Baumritter; Graham Quinn
Journal:  J AAPOS       Date:  2016-10-01       Impact factor: 1.220

7.  Plus Disease in Retinopathy of Prematurity: A Continuous Spectrum of Vascular Abnormality as a Basis of Diagnostic Variability.

Authors:  J Peter Campbell; Jayashree Kalpathy-Cramer; Deniz Erdogmus; Peng Tian; Dharanish Kedarisetti; Chace Moleta; James D Reynolds; Kelly Hutcheson; Michael J Shapiro; Michael X Repka; Philip Ferrone; Kimberly Drenser; Jason Horowitz; Kemal Sonmez; Ryan Swan; Susan Ostmo; Karyn E Jonas; R V Paul Chan; Michael F Chiang
Journal:  Ophthalmology       Date:  2016-08-31       Impact factor: 12.079

8.  Telemedicine approach to screening for severe retinopathy of prematurity: a pilot study.

Authors:  Anna L Ells; Jonathan M Holmes; William F Astle; Geoff Williams; David A Leske; Michael Fielden; Brad Uphill; Penny Jennett; Marilynne Hebert
Journal:  Ophthalmology       Date:  2003-11       Impact factor: 12.079

9.  Validity of a telemedicine system for the evaluation of acute-phase retinopathy of prematurity.

Authors:  Graham E Quinn; Gui-shuang Ying; Ebenezer Daniel; P Lloyd Hildebrand; Anna Ells; Agnieshka Baumritter; Alex R Kemper; Eleanor B Schron; Kelly Wade
Journal:  JAMA Ophthalmol       Date:  2014-10       Impact factor: 7.389

10.  Analysis of Discrepancy Between Diagnostic Clinical Examination Findings and Corresponding Evaluation of Digital Images in the Telemedicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity Study.

Authors:  Graham E Quinn; Anna Ells; Antonio Capone; G Baker Hubbard; Ebenezer Daniel; P Lloyd Hildebrand; Gui-Shuang Ying
Journal:  JAMA Ophthalmol       Date:  2016-11-01       Impact factor: 7.389

View more
  1 in total

1.  Progression from preplus to plus disease in the Telemedicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity (e-ROP) Study: incidence, timing, and predictors.

Authors:  Qianqian Ellie Cheng; Graham E Quinn; Ebenezer Daniel; Agnieshka Baumritter; Eli Smith; Gui-Shuang Ying
Journal:  J AAPOS       Date:  2020-11-16       Impact factor: 1.220

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.